Apple Podcasts - Program: OncoAlert, Avsnitt: The OncoAlert Podcast for ASCO #GU21 – 23 feb...
# GU21
Medscape - Two new approaches to surveillance imaging after treatment of stage I testicular seminoma sharply reduced or eliminate radiation exposure in the phase 3 TRISST...
-
Two new approaches to surveillance imaging after treatment of stage I testicular seminoma described in the 3 TRISST study may sharply reduce or eliminate radiation exposure. https://t.co/C5pZOyCs3T #GU21
UroToday - ASCO GU 2021 Genitourinary Cancers Symposium, Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Radiology “Write This Down” – What Do Nonradiologists...
-
Critical pathways in #RenalCellCarcinoma – Radiology “Write This Down” - What do non-radiologists need to know. Presented by Theodora Potretzke, MD, Phd @MayoClinic. #GU21 written coverage by @aloktewar @DanaFarber on UroToday > https://t.co/WncFuRuiVd @ASCO https://t.co/WncFuRuiVd
VJOncology - Sangeeta Goswami, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an outline of the state...
-
VIDEO: State of the art research in bladder cancer treatment w/ Sangeeta Goswami of @MDAndersonNews: 👉https://t.co/FU6egJ9ytw👈 @VJOncology @OncoAlert #GU21 #UroSoMe #UroOnc #OncoAlert #Oncology #BLCsm #BladderCancer #ClinOnc #MedOnc #ImmunoOnc #CaxTx #ASCOGU
jnccn360.org - By: Sarah Campen, PharmD Posted: Wednesday, February 24, 2021 Cabozantinib appears to prolong progression-free survival in patients with metastatic papillary renal cell carcinoma compared...
-
#cabozantinib emerges from SWOG 1500 Trial of metastatic papillary #kidneycancer: https://t.co/yCnKWFcKky #GU21 #kcsm #JNCCN360 https://t.co/yCnKWFcKky
UroToday - ASCO GU 2021 Genitourinary Cancers Symposium, Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Quality of Life Corner, treatment decisions for the...
-
Bench to Bedside: Critical pathways in #RenalCellCarcinoma – Quality of Life corner. Presentation by Jodi Maranchie, MD @PittTweet. #GU21 written coverage by @aloktewar @DanaFarber on UroToday > https://t.co/bBmG7tl9SQ @ASCO #ASCOGU https://t.co/bBmG7tl9SQ
UroToday - ASCO GU 2021 Genitourinary Cancers Symposium, Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Cure the Cancer or Avoid Dialysis? Helping Decide,...
-
Critical pathways in #RenalCellCarcinoma – Cure cancer or avoid dialysis? Helping decide. Presentation by Susie Hu, MD, FASN, BRCU @brown_kidney. #GU21 written coverage by @aloktewar @DanaFarber on UroToday > https://t.co/BxUO9HioJk @ASCO https://t.co/BxUO9HioJk
Medscape - The antibody-drug conjugate enfortumab vedotin is superior to chemotherapy in patients with previously treated advanced urothelial carcinoma, primary results of the EV-301 trial...
-
Enfortumab vedotin is superior to chemotherapy for previously treated advanced urothelial carcinoma, primary results of the EV-301 trial show. https://t.co/hkMlhkPNOV #GU21 https://t.co/hkMlhkPNOV
UroToday - ASCO GU 2021 Genitourinary Cancers Symposium, Best of the Journals: Renal Cell Carcinoma – Surgery, active surveillance for T1aN0M0 RCC, Growth Rates of Genetically...
-
Best of the Journals: #RenalCellCarcinoma. Surgery presentation by @BBhindi @UCalgary highlighting practice influencing papers on #KidneyCancer surgery in the last year. #GU21 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/JZcN3KhIWv @ASCO https://t.co/JZcN3KhIWv
Renal and Urology News - Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell...
-
Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC https://t.co/tHQiu8blwW #kcsm #GU21
Our MOST Popular @OncoAlert 🚨PODCAST yet‼️ Tune in as @DrChoueiri @TiansterZhang @montypal & @neerajaiims discuss the biggest trials from🇺🇸 @ASCO #GU21 Apple🍏 https://t.co/Z41gTDdBRF Spotify🎙️ https://t.co/Z41gTDdBRF Direct MP3 https://t.co/Z41gTDdBRF We Are OncoAlert🌐 https://t.co/Z41gTDdBRF